Clinical trials
catalyst calendar across sponsors →Studies where BNTC is the lead sponsor, as filed with ClinicalTrials.gov. Completion dates are the sponsor's own projected windows and are revised as a study runs. Active studies first, then completed and stopped — newest readout first within each.
2 interventional
Held by 5 tracked-famous managers (MILLENNIUM MANAGEMENT LLC, Balyasny Asset Management L.P., Schonfeld Strategic Advisors LLC, CITADEL ADVISORS LLC, AQR CAPITAL MANAGEMENT LLC) · FINRA short interest 26.7 days to cover (settled 2026-07-31) · government filings 180d: none disclosed
| Study | Phase | Status | Interventions | Conditions | Enrollment | Primary completion | Readout in | Updated |
|---|---|---|---|---|---|---|---|---|
| A Study to Evaluate the Safety and Clinical Activity of Intramuscular Doses of BB-301 Administered to Subjects With Oculopharyngeal Muscular Dystrophy With DysphagiaNCT06185673Incidence of dose-limiting toxicities (DLTs) in phase 1bOpen-label · Treatment | Phase 1/2 | Recruiting | Genetic: BB-301: Dose escalation phase 1b cohort 1, BB-301: Dose escalation phase 1b cohort 2, BB-301: Dose escalation phase 1b cohort 3, BB-301: Dose expansion phase 2a | Oculopharyngeal Muscular Dystrophy | 30 | Nov 2030 | ≤ 1,564 d | 2025-12-31 |
| A Study of BB-401 in Recurrent or Metastatic Head and Neck Squamous Cell CarcinomaNCT03433027Overall Response (OR) of the injected tumorOpen-label · Treatment | Phase 2 | Completed | Drug: BB-401 | Head and Neck Squamous Cell Carcinoma | 16 | 2018-12-12actual | — | 2020-04-15 |
Primary completion is the date the sponsor filed with the registry — their own projection, revised whenever they revise it, unless the row is marked actual.
Source: ClinicalTrials.gov, retrieved 2026-08-19